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Abstract Amino acid transport is an attractive target for
oncologic imaging. Despite a high demand of cancer cells for
cationic amino acids, their potential as PET probes remains
unexplored. Arginine, in particular, is involved in a number of
biosynthetic pathways that significantly influence carcino-
genesis and tumor biology. Cationic amino acids are trans-
ported by several cationic transport systems including,
ATB0,? (SLC6A14), which is upregulated in certain human
cancers including cervical, colorectal and estrogen receptor-
positive breast cancer. In this work, we report the synthesis
and preliminary biological evaluation of a new cationic ana-
log of the clinically used PET tumor imaging agent O-(2-
[18F]fluroethyl)-L-tyrosine ([18F]FET), namely O-2((2-
[18F]fluoroethyl)methylamino)ethyltyrosine ([18F]FEMAET).
Reference compound and precursor were prepared by multi-
step approaches. Radiosynthesis was achieved by no-carrier-
added nucleophilic [18F]fluorination in 16–20 % decay-cor-
rected yields with radiochemical purity [99 %. The new
tracer showed good stability in vitro and in vivo. Cell uptake
assays demonstrated that FEMAET and [18F]FEMAET
accumulate in prostate cancer (PC-3) and small cell lung
cancer cells (NCI-H69), with an energy-dependent mecha-
nism. Small animal PET imaging with NCI-H69 xenograft-
bearing mice revealed good tumor visualization comparable
to [18F]FET and low brain uptake, indicating negligible
transport across the blood–brain barrier. In conclusion, the
non-natural cationic amino acid PET probe [18F]FEMAET
accumulates in cancer cells in vitro and in vivo with possible
involvement of ATB0,?.
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Abbreviations
[18F]FDG 2-[18F]fluoro-2-deoxy-D-glucose
mTOR Mammalian target of rapamycin
LAT1 System L amino acid transporter
[18F]FET O-(2-[18F]fluroethyl)-L-tyrosine
CAT Cationic amino acid transporter family
NO Nitric oxide
[18F]AFETP (S)-2-amino-3-[1-(2-[18F]fluoroethyl)-
1H-[1,2,3]triazol-4-yl]propanoic acid
[18F]FEMAET O-2((2-[18F]fluoroethyl)methylamino)
ethyltyrosine
DEAD Diethyl azodicarboxylate
KCN Potassium cyanide
DIPEA Diisopropylethylamine
DAST Diethylaminosulfurtrifluoride
CBr4 Carbon tetrabromide
PPh3 Triphenylphosphine
[18F]FDOPA L-3,4-Dihydroxy-6-
[18F]fluorophenylalanine
EBSS EARLE balanced salt solution
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Among the various imaging modalities, PET is a radio-
tracer-based imaging method that has been recognized as a
powerful tool, able to provide molecular and physiological
information for diverse cancer lesions (McConathy and
Goodman 2008; McConathy et al. 2012). Since a common
feature of cancer cells is a high demand for nutrients (e.g.,
glucose, amino acids, fatty acids, vitamins and micronu-
trients) to support their fast growth and proliferation, there
is a strong rationale for using such compounds as PET
probes (Ganapathy et al. 2009; Plathow and Weber 2008).
Radiolabeled amino acids are a promising class of
tracers for imaging upregulated metabolism associated
with several hallmarks of cancer. These tracers have the
potential to overcome some of the limitations of
2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), the most
commonly used oncologic PET tracer, mainly because of
their low uptake in healthy brain and inflammatory tissue
(Kaim et al. 2002; Lee et al. 2009; Shreve et al. 1999).
Moreover, some of them may be useful for slowly growing
tumors such as renal cell carcinoma and endocrine tumors
where [18F]FDG shows low or variable uptake (Koopmans
et al. 2009; Schoder and Larson 2004; Sundin et al. 2004,
2007). There is also increasing evidence that the enhanced
uptake of amino acids is correlated with signaling path-
ways involved in tumor growth, including the mammalian
target of rapamycin (mTOR) pathway (Beugnet et al. 2003)
and may have prognostic significance.
Amino acids generally enter cells through membrane-
associated carrier proteins, and more than 20 distinct amino
acid transporters have been identified in mammalian cells
differing in terms of substrate specificity, tissue expression
patterns, dependence on sodium and other ions, sensitivity to
pH and mechanism of transport (McConathy et al. 2012).
Tumor cells have a distinct metabolic need for amino acids
to support their rapid growth, serving different needs such as
protein synthesis, energy production, cell signaling and as a
carbon and nitrogen source for cell growth (Ganapathy et al.
2009). This high demand is met by an enhanced cellular
entry of amino acids through upregulation of certain of the
aforementioned transporters (Busch et al. 1959; Fuchs and
Bode 2005; Saier et al. 1988). Among these, the L-type
amino acid transporter 1 (LAT1), an obligatory exchange,
sodium-independent neutral amino acid transporter, has
been the center of attention because of its critical role in
angiogenesis, tumor growth and proliferation (Kim et al.
2004; Kobayashi et al. 2008; Nawashiro et al. 2006; Tamai
et al. 2001; Fuchs and Bode 2005). A number of labeled
amino acids targeting system L have demonstrated promis-
ing clinical utility with O-(2-[18F]fluroethyl)-L-tyrosine
([18F]FET) (Langen et al. 2006; Wester et al. 1999) being
one of the most successful examples (Fig. 1).
Recently, there has been growing interest in other amino
acid transport systems which are implicated in cancer
growth, including xCT, (Ganapathy et al. 2009; Nakanishi
and Tamai 2011) glutamine (Wise and Thompson 2010)
and cationic amino acid transporters. The entry of basic
amino acids (L-lysine, L-histidine and L-arginine) into cells
can be mediated by several sodium-independent or sodium-
dependent transporter systems, including the cationic
amino acid transporter (CAT) family, system y?L, b0,?AT,
and ATB0,? (Closs 2002; Closs et al. 2006; Kanai et al.
2000). Both L-lysine and L-histidine are essential amino
acids that cannot be synthesized by human cells. L-argi-
nine, although conditionally essential, is the sole precursor
for the multifunctional messenger molecule nitric oxide
(NO) which, in certain human cancer cells, may influence
tumor initiation, promotion, and progression, tumor-cell
adhesion, apoptosis and angiogenesis (Lind 2004). Argi-
nine plays also a vital role for cells lacking the enzyme
argininosuccinate synthase, which is absent in many can-
cers (Dillon et al. 2004). Moreover, there is emerging
evidence for tumor-associated up-regulation of the ATB0,?
transporter and its expression was found to be markedly
induced in colorectal (Gupta et al. 2005), cervical (Gupta
et al. 2006) and estrogen receptor-positive breast cancer
(Karunakaran et al. 2011). In this respect, cationic amino
acid transport could be a promising target for oncologic
imaging in terms of detection, prognosis and response to
therapy monitoring of related tumors. Its potential though
remains largely unexplored mainly because of the lack of
well characterized imaging agents.
Our goal was to investigate the biological behavior of a
[18F]-labeled cationic amino acid derivative and to eval-
uate its potential for cancer imaging. To our knowledge,
there is only one [18F]-labeled basic amino acid analog
under investigation as a potential PET probe for tumor
imaging, the triazole derivative (S)-2-amino-3-[1-(2-
[18F]fluoroethyl)-1H-[1,2,3]triazol-4-yl]propanoic acid
([18F]AFETP, Fig. 1) (McConathy et al. 2010; Solin-
gapuram Sai et al. 2011). Biological evaluation showed
that the uptake of [18F]AFETP is mediated by several
transport systems, both for neutral and cationic amino
acids. This could be attributed to the weakly basic nature
of the triazole moiety, probably rendering it neutral at
physiological pH (Comer 2007) and possibly more basic
amino acid derivatives are needed to efficiently target
cationic amino acid transporters. For our purposes, we
chose the successful PET tumor imaging agent and LAT1
substrate [18F]FET as a lead structure for further deriva-
tization towards a cationic surrogate. Therefore, tyrosine
was combined with an aliphatic tertiary amine, namely
diethanolmethylamine to give O-2((2-[18F]fluoroeth-
yl)methylamino)ethyl L-tyrosine ([18F]FEMAET, Fig. 1).
The presence of a tertiary nitrogen atom is expected to
render [18F]FEMAET cationic at physiological pH
(Comer 2007; Smith and March 2007) which would most
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probably exclude its uptake through the LAT or other
neutral amino acid transporters.
In this work, we describe the synthesis, radiolabelling
and preliminary biological evaluation of [18F]FEMAET as
a potential tracer for cationic amino acid uptake. To our
knowledge, ATB0,? is the only transporter for cationic
amino acids that is upregulated by cancer cells (Ganapathy
et al. 2009; Nakanishi and Tamai 2011; Sloan and Mager
1999). We were, therefore, particularly interested to
investigate possible implication of this transporter in the
uptake of the new cationic tracer. For this reason, the small
cell lung cancer NCI-H69 and the prostate cancer cell line
PC-3 were chosen for the preliminary in vitro and in vivo
studies, as they both express ATB0,? on the mRNA level
(Mu¨ller et al. 2013).
Materials and methods
General
All reagents and starting materials were purchased from
commercial suppliers and used without further purification.
All solvents used for reactions were purchased as anhydrous
grade from Acros Organics (puriss., dried over molecular
sieves, H2O \ 0.005 %) and were used without further
purification unless otherwise stated. Solvents for extractions,
column chromatography and thin layer chromatography
(TLC) were purchased as commercial grade. All non-aque-
ous reactions were performed under an argon atmosphere
using flame-dried glassware and standard syringe/septa
techniques. In general, reactions were magnetically stirred
and monitored by TLC performed on Merck TLC glass
sheets (silica gel 60 F254). Spots were visualized with UV
light (k = 254 nm) or through staining with anisaldehyde
solution or basic aq. KMnO4 solution and subsequent
heating. Chromatographic purification of products was per-
formed using Fluka silica gel 60 for preparative column
chromatography (particle size 40–63 lm). Reactions at 0 C
were carried out in an ice/water bath. Reactions at -78 C
were carried out in a dry ice/acetone bath. Nuclear magnetic
resonance (NMR) spectra were recorded in CDCl3 or
CD3OD on a Bruker Av-400 spectrometer at room temper-
ature. The measured chemical shifts are reported in d (ppm)
and the residual signal of the solvent was used as the internal
standard (CDCl3
1H: d = 7.26 ppm, 13C: d = 77.0 ppm,
CD3OD
1H: d = 3.31 ppm, 13C: d = 49.15 ppm). For the
19F NMR spectra, CFCl3 (=0.00 ppm) was used as the
internal standard. All 13C NMR spectra were measured with
complete proton decoupling. Data of NMR spectra are
reported as follows: s singlet, d doublet, t triplet, q quartet,
m multiplet, dd doublet of doublets, dt doublet of triplets, br
broad signal. The coupling constant J is reported in Hertz
(Hz). Electrospray (ES) mass spectra (HRMS) were obtained
with a Bruker’s maXis (ESI-Qq-TOF-MS) spectrometer.
Analytical radio-HPLC was performed on an Agilent
1100 system equipped with multi-UV-wavelength and
Raytest Gabi Star detectors and Gina Star software. A
reverse phase column was used (LiChrospher 100 RP-18
5 lm LiChroCART 4 9 250 mm) with the following
solvent system: H2O (NH4HCO3 50 mM) (solvent A), ace-
tonitrile (solvent B); flow 1 ml/min; 0–3 min: 5 % B,
3–15 min: 5–90 % B, 15–19 min: 90 % B, 19–20 min:
90–5 % B; UV = 254 nm. Semi-preparative purification of
radiolabeled material was performed on a Merck-Hitachi
L6200A system equipped with Knauer variable wavelength
detector and an Emberline radiation detector using a reverse
phase column (Phenomenex Luna C18, 10 9 250 mm,
5 lm) and a mobile phase consisting of the following sys-
tem: H2O (NH4HCO3 50 mM) (solvent A), acetonitrile
(solvent B); flow 4 ml/min; 0–5 min: 5 % B, 5–10 min:
5–65 % B, 10–30 min: 65 % B; UV = 254 nm. For
Fig. 1 Structures of
[18F]AFETP, [18F]FET and its
new cationic analog
[18F]FEMAET
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reaction monitoring during radiosynthesis and for analysis of
samples during radiometabolite and in vitro stability studies,
a Waters Ultra-performance liquid chromatography
(UPLC) system was used with an Acquity UPLC BEH C18
column (2.1 9 50 mm, 1.7 lm, Waters) and an attached
coincidence detector (FlowStar LBS13, Berthold). The
mobile phase consisted of the following system: H2O
(NH4HCO3 50 mM) (solvent A), acetonitrile (solvent B);
flow 0.6 ml/min; 0–0.3 min: 0 % B, 0.3–2.2 min: 0–70 %
B, 2.2–2.7 min: 70 % B, 2.7–2.90 min: 70–0 % B;
2.90–3.00 min 0 %B; UV = 254 nm. Specific activity was
calculated by comparing ultraviolet peak intensity of final
formulated products with calibration curves of correspond-
ing non-radioactive standards of known concentrations.
Chemistry
2-((2-Hydroxyethyl)(methyl)amino)ethyl acetate (1)
To a solution of N-methyldiethanolamine (9.97 g,
83.69 mmol) in ethyl acetate (20 ml), acetic anhydride
(4.32 g, 42.40 mmol) was added dropwise at 0 C. The
reaction mixture was then allowed to reach room temperature
and was stirred for 3 h. After this time, the reaction mixture
was diluted with ethyl acetate and washed three times with
saturated NaHCO3 (aq.) solution, followed by water and brine.
The combined organic phases were dried over sodium sulfate,
filtered and concentrated. The crude product was purified by
flash column chromatography on silica gel (dichloromethane/
methanol = 93:7) to afford (1) (2.26 g, 33 %) as a clear oil.
1H NMR (CDCl3, 400 MHz) d 2.07 (s, 3H, CH3(C=O)O),
2.37 (s, 3H, CH3N), 2.64 (t, J = 5.4 Hz, 2H, HOCH2CH2N),
2.75 (t, J = 5.7 Hz, 2H, CH3C(=O)OCH2CH2N), 3.41 (br,
1H, OH), 3.61 (t, J = 5.4 Hz, 2H, HOCH2CH2N), 4.20 (t,
J = 5.7 Hz, 2H, CH3C(=O)OCH2CH2N).
13C NMR (CDCl3,
100 MHz) d 21.1, 42.2, 55.8, 58.5, 59.0, 62.1, 171.2. ESI-
QTOF MS m/z calculated for C7H16NO3 [M?H]
? 162.1121,
measured 162.1121.
Tert-butyl 2-((tert-butoxycarbonyl)amino)-3-(4-
hydroxyphenyl) propanoate (2)
To a mixture of tyrosine tert-butyl ester (1.76 g,
7.43 mmol) and NaHCO3 (1.71 g, 20.39 mmol) in DMF
(14 ml), di-tert-butyl dicarbonate (1.50 g, 6.86 mmol) was
added at 0 C. After 10 min, the reaction mixture was
allowed to reach room temperature and the suspension was
stirred for 40 h. After this time, the reaction mixture was
diluted with ethyl acetate and washed four times with water
and once brine then dried over magnesium sulfate, filtered
and evaporated to dryness under reduced pressure. The
residue was purified with flash column chromatography on
silica gel (hexane/ethyl acetate = 7/3) to afford 2 (2.15 g,
93 %) as a white solid. 1H NMR (CDCl3, 400 MHz) d 1.41
(s, 9H, C(CH3)3), 1.42 (s, 9H, C(CH3)3), 2.91–3.04 (m, 2H,
ArCH2CH), 4.40 (q, J1 = 8.2 Hz and J2 = 6.2 Hz, 1H,
ArCH2CH), 5.00 (d, J = 8.2 Hz, 1H, NHBoc), 5.36 (s, 1H,
ArOH), 6.73 (d, J = 8.3 Hz, 2H, ArH), 7.02 (d,
J = 8.3 Hz, 2H, ArH). 13C NMR (CDCl3, 100 MHz) d
28.1, 28.5, 37.9, 55.2, 80.0, 82.3, 115.4, 128.5, 130.8,
154.9, 155.4, 171.3.ESI-QTOF MS m/z calculated for
C18H28NO5 [M?H]
? 338.1962, measured 338.1961.
Tert-butyl3-(4-(2-((2-
acetoxyethyl)(methyl)amino)ethoxy)phenyl)-2-
((tertbutoxycarbonyl)amino)-propanoate (3)
Triphenylphosphine (3.27 g, 12.46 mmol) was added to a
mixture of compounds 1 (2.00 g, 12.41 mmol) and 2
(4.21 g, 12.46 mmol), dissolved in tetrahydrofuran (26 ml).
To this mixture, a solution of diethyl azodicarboxylate
(DEAD) (2.18 g, 12.51 mmol) in tetrahydrofuran (14 ml)
was added dropwise at room temperature within 15 min.
The reaction mixture was stirred for 63 h and then con-
centrated on a rotary evaporator and taken up in a mixture of
diethyl ether and ethyl acetate. The mixture was washed
three times with 0.2 M HCl. The combined aqueous phases
were washed twice with diethyl ether and turned basic by
adding solid NaHCO3 and then extracted three times with
ethyl acetate. The combined extracts were washed once with
brine, dried over sodium sulfate, filtered and concentrated to
dryness. The crude product was purified by flash column
chromatography on silica gel (hexane/ethyl acetate = 5/5,
changing gradually to 4/6 and 4/6 with Et3N 1 %) to afford 3
(4.11 g, 68 %) as a colorless clear oil.1H NMR (CDCl3,
400 MHz) d 1.41 (s, 9H, C(CH3)3), 1.42 (s, 9H, C(CH3)3),
2.05 (s, 3H,CH3C(=O)O), 2.41 (s, 3H, CH3N), 2.77 (t,
J = 5.8 Hz, 2H, CH3C(=O)OCH2CH2N), 2.86 (t,
J = 5.8 Hz, 2H, ArOCH2CH2N), 2.94–3.04 (m, 2H,
ArCH2CH), 4.04 (t, J = 5.8 Hz, 2H, ArOCH2CH2N), 4.19
(t, J = 5.8 Hz, 2H, CH3C(=O)OCH2CH2N), 4.40 (q,
J1 = 8.0 Hz and J2 = 6.0 Hz, 1H, ArCH2CH), 4.95 (d,
J = 8.0 Hz, 1H, NHBoc), 6.82 (d, J = 8.6 Hz, 2H, ArH),
7.07 (d, J = 8.6 Hz, 2H, ArH).13C NMR (CDCl3,
100 MHz) d 21.2, 28.1, 28.5, 37.3, 43.3, 55.1, 56.2, 56.6,
62.4, 66.2, 79.8, 82.2, 114.6, 128.7, 130.7, 155.3, 157.9,
171.2, 171.3. ESI-QTOF MS m/z calculated for
C25H41N2O7 [M?H]
? 481.2908, measured 481.2913.
Tert-butyl-2-((tert-butoxycarbonyl)amino)-3-(4-(2-((2-
hydroxy-ethyl)(methyl)amino)ethoxy)phenyl)-propanoate
(4)
To a stirred solution of compound 3 (4.28 g, 8.90 mmol) in
methanol (36 ml), potassium cyanide (0.29 g, 4.46 mmol)
was added at room temperature. The reaction mixture was
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stirred overnight and then evaporated to dryness under
reduced pressure. The crude product was dissolved in
dichloromethane and filtered through a short pad of silica
gel to afford 4 (3.72 g, 95 %) as a clear oil. 1H NMR
(CDCl3, 400 MHz) d 1.41 (s, 9H, C(CH3)3), 1.42 (s, 9H,
C(CH3)3), 2.38 (s, 3H,CH3N), 2.65 (t, J = 5.2 Hz, 2H,
HOCH2CH2N), 2.86 (t, J = 5.6 Hz, 2H, ArOCH2CH2N),
2.95-3.05 (m, 2H, ArCH2CH), 3.60 (t, J = 5.2 Hz, 2H,
HOCH2CH2N), 4.03 (t, J = 5.6 Hz, 2H, ArOCH2CH2N),
4.40 (q, J1 = 7.9 Hz and J2 = 6.3 Hz, 1H, ArCH2CH),
4.96 (d, J = 7.9 Hz, 1H, NHBoc), 6.82 (d, J = 8.6 Hz,
2H, ArH), 7.07 (d, J = 8.6 Hz, 2H, ArH).13C NMR
(CDCl3, 100 MHz) d 28.1, 28.4, 37.7, 42.5, 55.0, 56.3,
58.7, 59.2, 66.1, 79.7,82.1, 114.5, 128.7, 130.7, 155.2,
157.8, 171.1.Varian HiResMALDI MS m/z calculated for
C23H39N2O6 [M?H]
? 439.2803, measured 439.2807.
Tert-butyl-2-((tert-butoxycarbonyl)amino)-3-(4-(2-((2-
chloroethyl)(methyl)amino)ethoxy)phenyl)-propanoate (5)
A solution of methanesulfonyl chloride (130 mg,
1.14 mmol) in dichloromethane (1 ml) was added dropwise
within 10 min to a solution of compound 4 (416 mg,
0.95 mmol) and triethylamine (259 mg, 2.56 mmol) in
dichloromethane (5 ml) at -40 C. The reaction mixture
was left to stir overnight while the temperature reached
10 C. The mixture was diluted with dichloromethane,
washed once with 5 % NaHCO3 solution, water and brine,
dried over sodium sulfate, filtered and evaporated to dry-
ness. The crude was purified by flash column chromatog-
raphy (hexane/ethyl acetate/triethylamine 7:3:0.1) to afford
5 (270 mg, 62 %) as a clear oil.1H NMR (CDCl3,
400 MHz) d 1.41 (s, 9H, C(CH3)3), 1.42 (s, 9H, C(CH3)3),
2.42 (s, 3H, CH3N), 2.83–2.91 (m, 4H, ClCH2CH2N and
ArOCH2CH2N), 2.94–3.03 (br, 2H, ArCH2CH), 3.58 (t,
J = 7.0 Hz, 2H, ClCH2CH2N), 4.04 (t, J = 5.8 Hz, 2H,
ArOCH2CH2N), 4.40 (q, J1 = 7.7 Hz and J2 = 6.1 Hz,
1H, ArCH2CH), 4.96 (d, J = 7.7 Hz, 1H,NHBoc), 6.82 (d,
J = 8.4 Hz, 2H, ArH), 7.07 (d, J = 8.5 Hz, 2H, ArH).13C
NMR (CDCl3, 100 MHz) d 28.0, 28.4, 37.6, 41.6, 43.0,
55.0, 56.3, 59.4, 66.2, 79.6,82.0, 114.5, 128.4, 130.6,
155.1, 157.7, 171.1. ESI-QTOF MS m/z calculated for
C23H38ClN2O5 [M?H]
? 457.2464, measured 457.2463.
Tert-butyl-3-(4-(2-((2-bromoethyl)(methyl)
amino)ethoxy)phenyl)-2-(tert-butoxycarbonyl)amino)-
propanoate (6)
Triphenylphosphine (183.4 mg, 0.70 mmol) was added to
an ice-cooled solution of 4 (250.7 mg, 0.57 mmol) in DCM
(2.8 ml) and the solution was stirred for 15 min. Under
protection from light, CBr4 (288.3 mg, 0.869 mmol) was
then added portion wise. After stirring for 1 h at 0 C, the
reaction mixture was allowed to reach room temperature
where it was stirred for an additional hour. The reaction
mixture was then evaporated to dryness under reduced
pressure and the crude product was purified by flash col-
umn chromatography on silica gel (hexane/ethyl ace-
tate = 7/3) to afford 6 (186.4 mg, 65 %) as a clear
colorless oil. 1H NMR (CDCl3, 400 MHz) 1.41 (s, 9H,
C(CH3)3), 1.42 (s, 9H, C(CH3)3), 2.42 (s, 3H, CH3N), 2.88
(t, J = 5.7 Hz, 2H, ArOCH2CH2N), 2.93 (t, J = 7.6 Hz,
2H, BrCH2CH2N), 2.96–3.02 (br, 2H, ArCH2CH), 3.43 (t,
J = 7.6 Hz, 2H, BrCH2CH2N), 4.05 (t, J = 5.7 Hz, 2H,
ArOCH2CH2N), 4.40 (q, J1 = 7.9 Hz and J2 = 6.1 Hz,
1H, ArCH2CH), 4.96 (d, J = 7.9 Hz, 1H, NHBoc), 6.82 (d,
J = 8.6 Hz, 2H, ArH), 7.07 (d, J = 8.7 Hz, 2H, ArH). 13C
NMR (CDCl3, 100 MHz) 28.1, 28.5, 29.8, 37.7, 42.9, 55.1,
56.2, 59.5, 66.2, 79.7,82.1, 114.6, 128.7, 130.7, 155.2,
157.8, 171.2. ESI-QTOF MS m/z calculated for C23H38Br
N2O5 [M?H]
? 501.1959, measured 501.1953.
Tert-butyl-2-((tert-butoxycarbonyl)amino)-3-(4-(2-((2-
iodoethyl)(methyl)amino)ethoxy)phenyl)-propanoate (7)
Iodine (276.1 mg, 1.09 mmol) was added to a solution of
triphenylphosphine (286.4 mg, 1.09 mmol) and N-ethyldi-
isopropylamine (DIPEA) (163.2 mg, 1.26 mmol) in dichlo-
romethane (4.6 ml) at 0 C. Under strict exclusion of light, a
solution of compound 4 (396 mg, 0.9 mmol) in dichloro-
methane (2.6 ml) was added dropwise. After 10 min of
stirring at 0 C, the reaction mixture was allowed to reach
room temperature and stirred for 4 h. The solvent was then
removed with a stream of argon and the crude was purified
by flash column chromatography on silica gel (hexane/ethyl
acetate = 7.5/2.5) to afford 7 (304.2 mg, 61 %) as a yel-
lowish oil. 1H NMR (CDCl3, 400 MHz) d 1.41 (s, 9H,
C(CH3)3), 1.42 (s, 9H, C(CH3)3), 2.40 (s, 3H,CH3N),
2.84–2.92 (m, 4H, ICH2CH2N and ArOCH2CH2N),
2.95–3.03 (br, 2H, ArCH2CH), 3.22 (t, J = 7.8 Hz, 2H,
ICH2CH2N), 4.05 (t, J = 5.7 Hz, 2H, ArOCH2CH2N), 4.40
(q, J1 = 7.6 Hz and J2 = 6.0 Hz, 1H, ArCH2CH), 4.96 (d,
J = 7.6 Hz, 1H, NHBoc), 6.82 (d, J = 8.6 Hz, 2H, ArH),
7.07 (d, J = 8.6 Hz, 2H, ArH). 13C NMR (CDCl3,
100 MHz) d 28.1, 28.5, 37.7, 42.5, 55.1, 55.8, 60.5, 66.3,
79.7,82.1, 114.6, 128.5, 130.7, 155.3, 157.8, 171.2. ESI-
QTOF MS m/z calculated for C23H38IN2O5 [M?H]
?
549.1820, measured 549.1831. Note Since the compound is
rather unstable, spectroscopic properties were measured
without any delays and by taking related precautions.
Tert-butyl-2-((tert-butoxycarbonyl)amino)-3-(4-(2-((2-
fluoroethyl)(methyl)amino)ethoxy)phenyl)-propanoate (8)
Method A Via fluorination of the iodo compound 7. To a
solution of compound 7 (304.2 mg, 0.56 mmol) in
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tetrahydrofuran (5.8 ml), AgF (93.6 mg, 0.74 mmol) was
added. The solution was stirred for 21 h at room temper-
ature under exclusion of light. After the reaction was
complete, the reaction mixture was filtered through a pad
of Celite and washed with ethyl acetate. The filtrate and
washings were combined and the solvent was removed
under reduced pressure. The crude product was purified by
flash column chromatography on silica gel (hexane/ethyl
acetate = 5/5) to afford 8 (105.7 mg, 43 %) as a clear oil.
1H NMR (CDCl3, 400 MHz) d 1.41 (s, 9H, C(CH3)3), 1.42
(s, 9H, C(CH3)3), 2.44 (s,3H, CH3N), 2.81 (t, J = 5.0 Hz,
1H, FCH2CH2N), 2.85–2.92 (m, 3H, ArOCH2CH2N and
FCH2CH2N (unresolved J because of overlapping),
2.95–3.03 (br, 2H, ArCH2CH), 4.06 (t, J = 5.9 Hz, 2H,
ArOCH2CH2N), 4.40 (q, J1 = 7.7 Hz and J2 = 6.1 Hz,
1H, ArCH2CH), 4.51 and 4.62 (dt,
2JH–F = 47.5 Hz and
3JH–H = 5.0 Hz, 2H, FCH2CH2N), 4.96 (d, J = 7.7 Hz,
1H,NHBoc), 6.82 (d, J = 8.5 Hz, 2H, ArH), 7.07 (d,
J = 8.6 Hz, 2H, ArH). 13C NMR (CDCl3, 100 MHz) d
28.1, 28.4, 37.7, 43.3, 55.1, 56.6, 57.7 (d,
2JC–F = 19.9 Hz), 66.3, 79.7, 82.0, 82.4 (d,
1JC-F =
167.7 Hz), 114.6, 128.7, 130.6, 155.3, 157.9, 171.2. 19F
NMR (CDCl3, 376 MHz) d (-219.63)–(-219.18) (m).
ESI-QTOF MS m/z calculated for C23H38FN2O5 [M?H]
?
441.2759, measured 441.2758.
Method B Via direct fluorination of the alcohol 4. A
solution of compound 4 (246.1 mg, 0.56 mmol) and N-
ethyldiisopropylamine (DIPEA) (259.7 mg, 2.01 mmol) in
dichloromethane (6.2 ml) was added dropwise, within
15 min, to a solution of diethylaminosulfurtrifluoride
(DAST) (315.8 mg, 1.96 mmol) in dichloromethane
(5.8 ml) at -78 C. After stirring for 15 min at that tem-
perature, the reaction was taken out of the cooling bath and
stirred for 3 h at room temperature. The reaction mixture
was then quenched with saturated NaHCO3 (aq.) solution
at 0 C. The mixture was diluted with ethyl acetate and
washed three times with saturated NaHCO3 (aq.) solution.
The organic phase was then washed once with water and
then brine, dried over Na2SO4, filtered and evaporated. The
crude product was purified by flash column chromatogra-
phy on silica gel (hexane/ethyl acetate 5:5) to afford 8
(70.8 mg, 29 %) as a clear oil. NMR analysis showed an
identical spectrum as in the case of method A.
2-amino-3-(4-(2-((2-
fluoroethyl)(methyl)amino)ethoxy)phenyl) propanoic acid
(FEMAET) (9)
Trifluoroacetic acid (1.31 g, 11.49 mmol) was added
dropwise to a solution of 8 (83.8 mg, 0.19 mmol) in
dichloromethane (1 ml) cooled at 0 C. After the addition,
the reaction was allowed to reach room temperature and
stirred for 16 h. Removal of the volatiles under reduced
pressure, afforded FEMAET as the TFA salt (94.3 mg,
97 %). 1H NMR (CD3OD, 400 MHz) d 3.06 (s, 3H,
CH3N), 3.12 (dd,
2J1 = 14.8 Hz and
3J2 = 7.5 Hz, 1H,
ArCH2CH), 3.25 (dd,
2JH–H = 14.8 Hz and
3JH–H = 5.7 Hz, 1H, ArCH2CH), 3.64 (br, 1H, FCH2-
CH2N), 3.71 (br, 3H, ArOCH2CH2N and FCH2CH2N),
4.20 (dd, J1 = 7.5 Hz and J2 = 5.8 Hz, 1H, ArCH2CH),
4.39 (t, J = 4.9 Hz, 2H, ArOCH2CH2N), 4.83 and 4.95 (dt,
2JH–F = 47.2 Hz and
3JH–H = 4.5 Hz, 2H, FCH2CH2N),
7.02 (d, J = 8.7 Hz, 2H, ArH), 7.27 (d, J = 8.7 Hz, 2H,
ArH). 13C NMR (CD3OD, 100 MHz) d 36.6, 42.0, 55.2,
56.7, 57.5 (d, 2JC–F = 19.6 Hz), 63.2,79.2 (d,
1JC–F = 168.8 Hz), 116.3, 129.0, 131.9, 158.7, 171.3.
19F
NMR (CD3OD, 376 MHz) d (-223.43)–(-222.98) (m).
Varian HiResMALDI MS m/z calculated for C14H22FN2O3
[M?H]? 285.1609, measured 285.1608.
Radiosynthesis of [18F]FEMAET
The conversion of 5 to [18F]-FEMAET was achieved via
nucleophilic substitution with [18F]-fluoride followed by
Boc-deprotection. [18F]-fluoride was obtained via the
18O(p,n) 18F reaction using 98 % enriched 18O-water. 18F-
was trapped on a light QMA cartridge (Waters), which was
preconditioned with 0.5 M K2CO3 (5 ml) and water (5 ml).
1 ml Kryptofix K2.2.2 solution [Kryptofix K2.2.2: 2.5 mg,
K2CO3: 0.5 mg in MeCN/water (2.3:1)] was used for the
elution of 18F- from the cartridge. The solvents were
evaporated at 110 C under vacuum with a slight inflow of
nitrogen gas. After addition of acetonitrile (1 ml), azeo-
tropic drying was carried out. This procedure was repeated
twice to afford dry [18F]KF-K2.2.2 complex. A solution of
chloride 5 (5 mg in 300 ll dry DMSO) was added to the
dried [18F]KF-K2.2.2 complex. The reaction mixture was
heated at 100 C for 10 min, followed by the addition of a
1:1 solution of MeCN:NH4HCO3 (50 mM) (2 ml). Purifi-
cation was performed by semi-preparative HPLC, with
[18F] 8 eluting at about 21 min which was collected in a
vial containing 40 ml of water. The product was trapped on
a C18 light SepPak cartridge (Waters), which was pre-
conditioned with ethanol (5 ml) and water (5 ml). After
washing the cartridge with 10 ml of water for removal of
traces of acetonitrile, the product was eluted with 1 ml of
acetone. The solvent was removed under reduced pressure
at 80 C and then TFA (0.7 ml) was added and the solution
was heated at 80 C for 10 min. TFA was then removed
under a flow of N2 and the residue was azeotroped with
1 ml of ethyl acetate at 80 C to remove traces of TFA. For
the final formulation, the radiolabeled compound was dis-
solved in 1 ml PBS 0.1 M (with 5 % EtOH) and filtered
through a sterile filter. Final pH was approximately 7.
Identification of [18F]FEMAET was confirmed by co-
injection with reference 9. Chemical and radiochemical
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purity were determined by analytical HPLC; tR = 9.30 min
for [18F]FEMAET. The radiochemical purity was always
[99 %. [18F]FET was obtained from a routine clinical
production from the University Hospital Zu¨rich,
Switzerland.
In vitro cell uptake studies
For [18F]FDOPA efflux experiments, cultures of PC-3 cells
(American Type Culture Collection) were incubated with
20 kBq [18F]FDOPA from a routine production for clinical
use (University Hospital Zu¨rich, Switzerland). After 1 h,
cells were washed twice with EBSS before 400 ll EBSS
containing 100 lM FEMAET in form of the TFA salt, pH
adjusted to 7.4, was added to each well (time zero). The
plates were incubated at the indicated temperature on a
shaker at 25 rpm and wells were washed twice with ice-
cold incubation solution at the indicated time points,
detached with trypsin/EDTA (Invitrogen) and radioactivity
was quantified in a gamma counter (Perkin Elmer Wizard
1480). Cell viability was confirmed at the end of the
incubation with trypan blue staining.
In vitro cell uptake of [18F]FEMAET was studied as
previously described (Kra¨mer et al. 2012). NCI-H69 cells
(German Collection of Microorganisms and Cell Cultures,
Cell Lines Service) were cultured in plastic tubes according
to the supplier’s protocol. Cells were sub-cultured the day
before the transport experiments. Before the uptake assay,
cells were washed twice and incubated with Earle’s bal-
anced salt solution containing Ca2? and Mg2? for 1 h at
37 C to deplete intracellular amino acids (EBSS, Invit-
rogen). At time zero, 20 MBq [18F]FEMAET was added to
each tube and the cells were incubated at 37 C at 25 rpm.
At the indicated time points, cells were washed twice with
ice-cold incubation solution, pelleted and radioactivity was
determined in a gamma counter. For protein quantification,
cells were lysed with 2 % sodium dodecyl sulfate and
analyzed with the DC Protein Assay (Bio-Rad) and bovine
serum albumin as standard.
In vitro metabolism
FEMAET was added at a final concentration of *1 lM to
a mixture of 50 lL NADPH regenerating system A (BD
Biosciences), 10 ll NADPH regenerating system B (BD
Biosciences), 200 ll TRIS buffer 375 mM and water in a
total volume of 975 ll at 37 C. At time 0, 25 ll human
liver microsomes (BD Biosciences, 20 mg protein per ml)
were added and the mix was incubated at 37 C and
600 rpm for 60 min. Aliquots of 100 ll were removed at
various time points and added to 100 ll ice-cold methanol
to stop enzymatic activity and precipitate proteins. The
samples were centrifuged and the supernatants filtered into
HPLC vials. Samples were analyzed with an analytical
Hitachi HPLC system (consisting of an autosampler
L-2200, pump L-2130, column oven L-2300, fluorescence
detector L-2480, UV detector L-2420) and a LiChro-
CART 250-4 HPLC-cartridge (Lichrospher 100, RP-
18e, 5 lm, 28 C). The mobile phase consisted of aceto-
nitrile (solvent A) and 0.1 % trifluoroacetic acid in water
(solvent B); flow 1.0 ml/min; 0–3 min: 95 % B, 3–13 min
95–85 % B, 13–18 min 80–20 % B, 18–21 min 20 % B,
21–22 min 20–95 % B, 22–30 min 95 % B. FEMAET was
quantified with a fluorescence detector (excitation 260 nm,
emission 300 nm). The experiment was performed in
triplicate. Enzymatic activity was confirmed with 2 lM
testosterone instead of FEMAET according to the sup-
plier’s protocol. Testosterone samples were run on a Water
Spherisorb ODS2 analytical cartridge (250 9 4.6 mm,
5 lm, 40 C) with sodium phosphate buffer (0.1 mM,
pH6), methanol, acetonitrile (50:38.5:11.5 (v/v/v)) at a
flow rate of 1.2 ml/min. Testosterone and its metabolites
were detected at 242 nm.
In vivo metabolism
[18F]FEMAET (23 and 43 MBq, respectively) was injected
into two NMRI nu/nu mice via tail vein. The mice were
killed by decapitation under isoflurane anesthesia 60 min
after tracer application and blood and urine were collected.
Plasma was separated from the blood samples by centri-
fugation and plasma and urine were extracted with ice-cold
acetonitrile at 1:1 volume ratios. The organic phases were
spotted on two silica gel TLC plates each (aluminum
sheets, silica gel 60, Merck Millipore) together with a trace
of [18F]FEMAET and developed in CHCl3/MeOH/acetic
acid/water, 60/50/1/4 and CHCl3/MeOH/NH3, 55/44/4.1,
respectively. Radioactivity was detected with a Canberra-
Packard Instant Imager (Perkin Elmer, Watford, UK).
In vivo PET studies
In vivo experiments were approved by the Veterinary
Office of the Canton Zu¨rich and were conducted in
accordance with the Swiss Animal Welfare legislation.
Female NMRI nu/nu mice (Charles River, Sulzfeld, Ger-
many) were inoculated at 6 weeks of age subcutaneously
with 1 9 107 NCI-H69 cells in 100 ll PBS with Ca2? and
Mg2? (Invitrogen; BP bioscience) on the right shoulder and
1 week later with the same cell number in matrigel (BD
Biosciences) on the left shoulder. PET/CT scans were
performed 2–5 weeks after inoculation, when the tumor
volumes reached [0.025 cm3. [18F]FEMAET (5.6 MBq,
0.1 ml) or [18F]FET (11.7 MBq, 0.1 ml) was injected into
a lateral tail vein and anesthesia (2–3 % isoflurane in
oxygen/air) was initiated 10 min before scan start.
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Respiratory frequency and temperature were monitored
and controlled as described previously (Honer et al. 2004).
[18F]FEMAET was scanned with a Vista eXplore PET/CT
camera (Sedecal, Spain, axial field of view 4.8 cm) in static
mode with two bed positions from 60 to 75 min p.i. for the
anterior body part including the tumor and 75–90 min for
the posterior body part. [18F]FET was scanned in list mode,
one bed position, from 30 to 120 min p.i. PET was fol-
lowed by CT acquisition for anatomical orientation. PET
data were reconstructed by 2-dimensional ordered-subsets
expectation maximization and analyzed with PMOD 3.4
(PMOD, Zu¨rich, Switzerland). Standardized uptake values
(SUV) were calculated for regions of interest as the ratio of
regional averaged Bq/cm3 and injected radioactivity in Bq
per g body weight. The [18F]FET tumor-to-tissue ratio was
highest from 60 to 75 min p.i., PET images were, therefore,
prepared from averaged data during this time window.
Results and discussion
Chemistry
FEMAET was synthesized starting from commercially
available tyrosine tert-butyl ester and diethanolmethyl-
amine as depicted in Scheme 1. Diethanolmethylamine
was first converted to the monoacetate 1 using acetic
anhydride which was then coupled to L-tyrosine-N-Boc
tert-butyl ester under Mitsunobu reaction conditions
(DEAD/PPh3) in THF yielding the key intermediate 3 in
68 % yield. Remarkably, the acetyl group in 3 proved quite
resilient and initial attempts to deacetylate 3 using standard
conditions such as K2CO3/MeOH or 1 M NaOH/MeOH
failed. Nevertheless, treating a solution of this compound
in MeOH with KCN as transesterification catalyst (Herzig
et al. 1986) allowed complete conversion and afforded the
free alcohol 4 in excellent yields. For the following step, it
was originally planned to introduce a sulfonate as an effi-
cient leaving group for the subsequent fluorination. How-
ever, mesylation of compound 4 afforded exclusively the
chlorinated analog 5 in 72 % yield. This unexpected
behavior has also been observed for other similar com-
pounds in the literature (Bacherikov et al. 2005; Savle et al.
1998). It is suggested that this conversion occurs via
spontaneous displacement of the sulfonate group by
nitrogen (anchimeric assistance) with formation of the
reactive intermediate aziridinium ion. Consequent collapse
of the aziridinium ion pair to the more stable chloride then
occurs, upon exchange of the tosylate counterion with
chloride (Boeckman et al. 2011).
Since introduction of a sulfonate group was not possible,
iodine was chosen as an efficient leaving group instead.
The iodinated analog 7 was successfully synthesized via
dehydroxylation—iodination reaction (Silhar et al. 2005).
Choosing an appropriate base seems to be important since
the conversion was more effective when using DIPEA
instead of imidazole. The iodo compound 7 proved to be
very sensitive to light and moisture so the reaction took
place under strict exclusion of light and purification was
performed without delays. Exchange of iodine to fluorine
was accomplished using AgF as a source of fluorine
yielding compound 8 in 43 % yield. To overcome the
problems associated with the sensitivity of the iodinated
compound, alcohol 4 was directly converted to 8 using
DAST as fluorinating agent (Okuda et al. 2009), albeit in
29 % yield which is comparable to the overall yield of the
conversion of 4–8 via the iodo compound. Finally, cleav-
age of the two tert-butyl groups with TFA yielded cleanly
the final compound 9 (FEMAET). As it was already
mentioned, the iodinated compound 7 is quite unstable, to a
point which makes its use as a radiolabeling precursor
rather impractical. For this reason, the analog brominated
compound 6 was also synthesized from alcohol 4 using
CBr4/PPh3, in hope to use this compound as an efficient
radiolabeling precursor. Unfortunately, 6 also proved to be
rather unstable as it was completely decomposed after
storage at -25 C within a short period of time. On the
other hand, the chlorinated compound 5 remained
unchanged under storage and it was thus decided to be used
as a radiolabeling precursor, despite the chlorine atom
being a poor leaving group.
Radiochemistry
[18F]FEMAET was prepared via nucleophilic substitution
of the chloride 5 with non-carrier-added [18F]KF-K2.2.2
complex in DMSO, followed by deprotection, as shown in
Scheme 2. The fluorinated intermediate [18F] 8 was puri-
fied by semi-HPLC purification, separating it efficiently
from its chloro-precursor despite their very similar chem-
ical properties. [18F] 8 was recovered from the HPLC
eluate using solid phase extraction with a C-18 light Sep-
Pak cartridge. The activity was eluted with EtOH, dried
and the intermediate was deprotected quantitatively using
TFA followed by evaporation, providing [18F]FEMAET in
a radiochemically pure form not requiring further purifi-
cation. For the final formulation, the residue was dissolved
inPBS 0.1 M (with 5 % EtOH) and filtered through a
sterile filter. Analytical samples after dose formulation of
[18F]FEMAET were stable for at least 4 h as assessed by
HPLC analysis. In a typical experiment, a radiochemical
yield of about 18 % (decay corrected) was achieved with a
radiochemical purity C99 % in a total synthesis and for-
mulation time of approximately 2 h. The specific activities
for [18F]FEMAET were in the range of 28–45 GBq/lmol
at the end of synthesis. The total synthesis time from end of
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bombardment was approximately 90 min. The identity of
the radiolabelled compound was confirmed by co-injection
with the reference compound 9.
In vitro cell uptake
Cell uptake studies were performed with PC-3 prostate
cancer and NCI-H69 small cell lung cancer cells. Both
cell lines express ATB0,? on the mRNA level (Mu¨ller
et al. 2013). Amino acid uptake into polarized cells is
often directly or indirectly coupled to the efflux of other
amino acids out of the cell (Wagner et al. 2001). Before
establishing the radiosynthesis, we investigated whether
FEMAET is able to enhance the efflux of preloaded
[18F]FDOPA, a substrate for LAT (Neels et al. 2008)
from PC-3 cells. Addition of 100 lM FEMAET acceler-
ated [18F]FDOPA efflux at 37 C (Fig. 2a) but not at
4 C, indicating energy-dependent uptake of FEMAET
into the cells with efflux of [18F]FDOPA in compensation.
However, the effect was weaker than that of the LAT
substrate L-leucine (Kra¨mer et al. 2012), which provoked
depletion of [18F]FDOPA within a few minutes at 37 and
4 C under otherwise identical experimental conditions
(Kra¨mer et al. 2012). This excludes efficient transport of
FEMAET by the obligatory exchange transporters LAT1
or LAT2.
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Scheme 1 Synthesis of FEMAET (9). Reagents and conditions:
a acetic anhydride, AcOEt, 0 C to room temperature, 3 h, 33 %;
b Boc anhydride, NaHCO3, DMF, 0 C to room temperature, 40 h,
93 %; c DEAD, PPh3, 1, THF, room temperature, 64 h, 68 %;
d KCN, MeOH, room temperature, 16 h, 95 %; e MsCl, Et3N, DCM,
-40 to 10 C, 15 h, 62 %; f PPh3, CBr4, DCM, 0 C to room
temperature, 2 h, 65 %; g PPh3, I2, DIPEA, DCM, 0 C to room
temperature, 4 h, 61 %; h AgF, THF, room temperature, 21 h, 43 %;
i DAST, DIPEA, DCM, -78 C to room temperature, 3 h, 29 %;
j TFA, DCM, 0 C to room temperature, 16 h, quantitative
Scheme 2 Radiosynthesis of [18F]FEMAET
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Consequently, we proceeded with the radiosynthesis of
[18F]FEMAET for further characterization. Uptake of
[18F]FEMAET in ATB0,?-positive NCI-H69 cells is depicted
in Fig. 2b. The new tracer efficiently accumulated in this
cancer cell line and the uptake was strikingly dependent on
the temperature, as already seen with the PC-3 cells, in
agreement with an energy-dependent uptake mechanism.
Due to the presence of a tertiary amine on the side chain
of [18F]FEMAET, the tracer is positively charged at
physiological pH with an expected pKa between 10 and 11
(Smith and March 2007). This most probably excludes its
transport by neutral amino acid transport systems like
LAT1 or ASCT2 which strictly carry neutral amino acids
(Ganapathy et al. 2009; Nakanishi and Tamai 2011; Verrey
et al. 2004). On the other hand, the energy dependency
observed in the uptake of [18F]FEMAET could indicate
possible involvement of the concentrative ATB0,? as a
transport mechanism since this is driven by the membrane
potential, in particular Na? and Cl- transmembrane gra-
dients (Sloan and Mager 1999). Certainly, transport of
cationic amino acids can also be mediated by several other
cationic amino acid transporters (CAT, y?L, b0,? AT)
besides ATB0,?. Nevertheless, these transport systems
maintain basal cationic amino acid availability and only
ATB0,? is able to concentrate amino acids intracellularly
utilizing the membrane potential as energy source (Nak-
anishi and Tamai 2011). In any case, more studies are
required to characterize the exact uptake mechanism of
[18F]FEMAET into cancer cells and healthy tissue.
In vitro and in vivo metabolism
Carbon atoms in a-position to ether oxygen atoms are
generally good targets for oxygenation by cytochrome
P450 monooxygenases (Testa and Kramer 2007). In the
case of FEMAET, such a transformation would generate
2-((2-fluoroethyl)(methyl)amino)ethanol and tyrosine. In
this respect, the stability of FEMAET in liver microsomes
was tested in vitro by incubating the compound with
human liver microsomes at 37 C. Results indicated that
FEMAET was stable without marked decomposition for
60 min; in particular, no tyrosine was formed. The meta-
bolic stability of [18F]FEMAET was also confirmed in vivo
in healthy mice. TLC analysis of plasma showed only
parent tracer but no metabolite 1 h after tracer application.
Only traces of radiometabolites were detected in urine
besides the parent tracer (data not shown).
PET imaging with NCI-H69 xenograft-bearing mice
Tumor accumulation of [18F]FEMAET was evaluated by
small animal PET with NCI-H69 xenograft-bearing mice.
As shown in Fig. 3a, [18F]FEMAET significantly accu-
mulated in the NCI-H69 xenograft exhibiting good tumor
visualization. No accumulation of radioactivity in bones
was observed which suggests that [18F]FEMAET does not
defluorinate in vivo. Figure 3b shows a PET scan with
[18F]FET under similar conditions. The SUV ratios
between xenografts and the neck were 2.1 and 2.6 for
[18F]FEMAET and [18F]FET, respectively, demonstrating
the good imaging potential of [18F]FEMAET. Figure 3c, d
shows the brain uptake of the two tyrosine analogs.
Transport of large neutral amino acids across the blood–
brain barrier is mediated by LAT1 (Hawkins et al. 2006;
Boado et al. 1999). As expected, [18F]FET radioactivity in
brain was similar as in peripheral tissues (Wester et al.
1999). In contrast, brain levels of [18F]FEMAET were
significantly lower than in peripheral tissues. This would be
expected for an ATB0,? substrate as the transporter is
absent in brain (Sloan and Mager 1999). The cationic
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Fig. 2 Indirect and direct evidence of FEMAET uptake into tumor
cells in vitro. a PC-3 cells were incubated with [18F]FDOPA at 37 C.
After 60 min, the medium was replaced by 100 lM FEMAET (2
independent experiments, error bars show single values) or amino
acid-free EBSS (4 independent experiments, mean and standard
deviations) and [18F]FDOPA remaining in the cells was determined at
37 and 4 C. b Uptake of [18F]FEMAET into NCI-H69 cells at 37 and
4 C (one experiment each)
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nature of [18F]FEMAET is most probably excluding its
transport by the system L amino acid transport.
Conclusion
In conclusion, our attempt to develop a novel [18F]-labeled
cationic amino acid derivative for tumor imaging has
proved to be encouraging. [18F]FEMAET, a cationic ana-
log of the well-established [18F]FET tracer, was prepared
by convenient procedures with satisfactory radiochemical
yield and specific activity. PET imaging in NCI-H69
tumor-bearing mice revealed good tumor visualization with
tumor/peripheral tissues ratio in the range of neutral amino
acid PET probes. This shows that, in principle, tumor
imaging is possible with a cationic PET probe. In addition,
the cationic nature of [18F]FEMAET in combination with
the preliminary biological evaluation suggests that the new
tracer could be potentially a substrate for cationic amino
acid transport. More importantly, there are indications that
the concentrative transporter ATB0,? is possibly involved
in [18F]FEMAET transport. Such a feature would make
[18F]FEMAET an attractive PET probe for the imaging of
malignant lesions that overexpress this transporter. Cer-
tainly more extensive biological assessment is needed to
elucidate its exact uptake mechanism and provide solid
proof about possible selectivity for the ATB0,? transporter.
Further pharmacological characterization of this novel
tracer is currently ongoing.
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Fig. 3 PET/CT images of NCI-H69 xenograft-bearing mice with
[18F]FEMAET (a, c) and [18F]FET (b, d). a, b Uptake into xenografts
(arrows); c, d same scans as in (a) and (b), brain (asterisk) uptake.
Injected doses were 5.6 MBq [18F]FEMAET and 11.7 MBq
[18F]FET. Color, PET; white/grey, CT. SUV scale was chosen to
have similar background colors in a, b and c, d, respectively (color
figure online)
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